Publicaciones científicas
-
Moreta-Moraleda, Cristina, Queralt, Cristina, Vendrell-Ayats, Carla, Forcales, Sonia and Martinez-Balibrea, Eva.
Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
Pharmacological Research 196:
-
Layos, L, Martinez-Balibrea, E and de Porras, VR.
Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?
International Journal of Molecular Sciences 23(22):
-
Bernat-Peguera, A, Trigueros, M, Ferrando-Diez, A, Ibanez, C, Bystrup, S, Martinez-Cardus, A, Margeli, M and Martinez-Balibrea, E.
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
Breast 62: 1-9
-
Domenech, M, Hernandez, A, Plaja, A, Martinez-Balibrea, E and Balana, C.
Hypoxia: The Cornerstone of Glioblastoma
International Journal of Molecular Sciences 22(22):
-
Ruiz de Porras V, Layos L and Martínez-Balibrea E.
Curcumin: A therapeutic strategy for colorectal cancer?
Seminars in Cancer Biology 73: 321-330
-
de Porras, VR, Wang, XC, Palomero, L, Marin-Aguilera, M, Sole-Blanch, C, Indacochea, A, Jimenez, N, Bystrup, S, Bakht, M, Conteduca, V, Piulats, JM, Buisan, O, Suarez, JF, Pardo, JC, Castro, E, Olmos, D, Beltran, H, Mellado, B, Martinez-Balibrea, E, Font, A and Aytes, A.
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
European Urology 79(6): 722-733
-
de Porras, VR, Bystrup, S, Cabrero-de las Heras, S, Musulen, E, Palomero, L, Alonso, MH, Nieto, R, Arango, D, Moreno, V, Queralt, C, Manzano, JL, Layos, L, Buges, C and Martinez-Balibrea, E.
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
Cancers 11(10):
-
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM and Rosell R.
Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Oncotarget 10(26): 2576-2576